Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch

Executive Summary

Company plans to meet with caregivers and consider other options before moving forward.

Advertisement

Related Content

Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Cost Versus Value: Earnings Calls Spotlight US Pricing Reforms
Time For Big Pharma To Take Back Orphan Drugs
GPhA Rebrands As AAM, Hopes To Change Tenor Of Drug Pricing Debate
Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register